Chemical adherence testing-guided intervention is cost-effective in management of non-adherence to antihypertensive treatment - life-time evaluation of OUTREACH Study

30 August 2026 (18:15 - 18:30)

Organised by:

About the speaker

Doctor Shadi Hames-Fathi

University of Manchester, Manchester (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail

Efficacy and safety of sacubitril/allisartan plus amlodipine in hypertensive patients not adequately controlled by amlodipine or sacubitril/allisartan monotherapy: the SALUS study

Professor J. Li (Beijing, CN)

Presentation thumbnail

The ELFIE-HYPERTENSION Trial: An international randomized multicenter trial of an artificial intelligence enhanced and gamified mobile health intervention for hypertension management

Doctor K. Santo (Sao Paulo, BR)

Presentation thumbnail

Blood pressure management with an artificial intelligence-enhanced app and wearable devices: My Intelligent Cardiac Assistant (MICArdiac) Randomised Controlled Trial

Doctor L. Laranjo (Sydney, AU)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: hypertension

The Event

Event poster

ESC Congress 2026

30 August 2026 18:15 CET

You may be interested in

Congress Presentation

Assesment of adherence to therapeutic recommendations among patients with hypertension

15 June 2024

Congress Presentation

Cost differences between oral anticoagulation therapies in atrial fibrillation patients

1 September 2024

Webinar

Arterial hypertension guidelines implementation. A case based approach

6 March 2020

Congress Presentation

Evaluating long-term outcomes: a prospective analysis of exercise and medication compliance in phase III cardiac rehabilitation

3 April 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources